All In Biotech

Drug Trial Radar · NCT01914419

Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum Hemorrhage

Administration of Oxytocin Via Intramuscular Injection and Intravenous Bolus or Intravenous Infusion in the Third Stage of Labor for Prevention of Postpartum Hemorrhage

Last checked: Nov 19, 2026Latest source record: Mar 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 4,983 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,983

Actual

Start

Apr 2014

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Gynuity Health ProjectsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
El Galaa Teaching Hospital; University of Alexandria
First posted
Aug 2, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will evaluate whether prophylactic oxytocin administered in the third stage of labor via intravenous (IV) infusion or IV bolus reduces the rate of postpartum hemorrhage compared to intramuscular (IM) injection.

Conditions

  • Postpartum Hemorrhage

Interventions

  • OxytocinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of women with postpartum blood loss equal to or greater than 500 mLTime frame: 1 hour after delivery of baby

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shatby Maternity Hospital, Alexandria University

    Alexandria, Egypt

  • El Galaa Teaching Hospital

    Cairo, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.